Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

On the horizon for multiple myeloma.

Mohundro MM, Mohundro BL.

Am J Manag Care. 2012 May;18(3 Spec No.):SP140-3. Review.

2.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Epub 2002 Apr 12. Review.

PMID:
12042984
3.

Treatment of multiple myeloma.

San Miguel JF, Bladé Creixenti J, García-Sanz R.

Haematologica. 1999 Jan;84(1):36-58. Review.

4.

Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.

Möller J, Nicklasson L, Murthy A.

J Med Econ. 2011;14(6):690-7. doi: 10.3111/13696998.2011.611841. Epub 2011 Sep 5.

PMID:
21892856
5.

Treatment of myeloma.

Smith ML, Newland AC.

QJM. 1999 Jan;92(1):11-4. Review.

PMID:
10209667
6.

Treatment of relapsed and refractory multiple myeloma in the era of novel agents.

van de Donk NW, Lokhorst HM, Dimopoulos M, Cavo M, Morgan G, Einsele H, Kropff M, Schey S, Avet-Loiseau H, Ludwig H, Goldschmidt H, Sonneveld P, Johnsen HE, Bladé J, San-Miguel JF, Palumbo A.

Cancer Treat Rev. 2011 Jun;37(4):266-83. doi: 10.1016/j.ctrv.2010.08.008. Epub 2010 Sep 21. Review.

PMID:
20863623
7.

Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.

Min CK, Lee MJ, Eom KS, Lee S, Lee JW, Min WS, Kim CC, Kim M, Lim J, Kim Y, Han K.

Jpn J Clin Oncol. 2007 Dec;37(12):961-8. Epub 2007 Dec 21.

PMID:
18156171
8.

Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.

Richardson P.

Semin Hematol. 2005 Oct;42(4 Suppl 4):S9-15. Review.

PMID:
16344100
9.

Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction.

Gertz MA, Kumar S, Lacy MQ, Dispenzieri A, Dingli D, Hayman SR, Buadi FK, Hogan WJ.

Blood. 2010 Mar 25;115(12):2348-53; quiz 2560. doi: 10.1182/blood-2009-07-235531. Epub 2010 Jan 20.

10.

Combined submyeloablative and myeloablative dose intense melphalan results in satisfactory responses with acceptable toxicity in patients with multiple myeloma.

Novitzky N, Thomson J, Thomas V, du Toit C, Mohamed Z, McDonald A.

Biol Blood Marrow Transplant. 2010 Oct;16(10):1402-10. doi: 10.1016/j.bbmt.2010.04.002. Epub 2010 Apr 10.

11.

Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial.

Chanan-Khan A, Miller KC, Musial L, Padmanabhan S, Yu J, Ailawadhi S, Sher T, Mohr A, Bernstein ZP, Barcos M, Patel M, Iancu D, Lee K, Czuczman MS.

Leuk Lymphoma. 2009 Jul;50(7):1096-101. doi: 10.1080/10428190902912460.

PMID:
19479618
12.

Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.

Alegre A, Granda A, Martínez-Chamorro C, Díaz-Mediavilla J, Martínez R, García-Laraña J, Lahuerta JJ, Sureda A, Bladé J, de la Rubia J, Fernández-Rañada JM, San Miguel J; Spanish Registry of Transplants in Multiple Myelomas; Spanish Group of Hemopoietic Transplant (GETH); PETHEMA.

Haematologica. 2002 Jun;87(6):609-14.

13.

Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.

Majolino I, Vignetti M, Meloni G, Vegna ML, Scimè R, Tringali S, Amaddii G, Coser P, Tribalto M, Raimondi R, Bergonzi C, Sajeva MR, Sica S, Ferrando F, Messina G, Mandelli F.

Haematologica. 1999 Sep;84(9):844-52.

14.

"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.

Gasparetto C, Gockerman JP, Diehl LF, de Castro CM, Moore JO, Long GD, Horwitz ME, Keogh G, Chute JP, Sullivan KM, Neuwirth R, Davis PH, Sutton LM, Anderson RD, Chao NJ, Rizzieri D.

Biol Blood Marrow Transplant. 2010 Jan;16(1):70-7. doi: 10.1016/j.bbmt.2009.08.017. Epub 2009 Sep 3.

15.

Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.

Dingli D, Rajkumar SV, Nowakowski GS, Gertz MA, Dispenzieri A, Lacy MQ, Hayman S, Fonseca R, Lust JA, Kyle RA, Greipp PR, Witzig TE.

Haematologica. 2005 Dec;90(12):1650-4.

16.

Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.

Chang H, Trieu Y, Qi X, Xu W, Stewart KA, Reece D.

Leuk Res. 2007 Jun;31(6):779-82. Epub 2006 Sep 22.

PMID:
16996589
17.

Clinical roundtable monograph. Emerging treatment options for relapsed and refractory multiple myeloma.

Siegel DS, Vij R, Jakubowiak AJ.

Clin Adv Hematol Oncol. 2011 Apr;9(4):1-15.

PMID:
21928467
18.

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.

Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D, Williams SF, Bensinger W, Badros AZ, Vescio R, Kenvin L, Yu Z, Olesnyckyj M, Zeldis J, Knight R, Anderson KC.

Blood. 2009 Jul 23;114(4):772-8. doi: 10.1182/blood-2008-12-196238. Epub 2009 May 26.

19.

Treatment of relapsed and refractory myeloma.

Reece DE, Leitch HA, Atkins H, Voralia M, Canning LA, LeBlanc R, Belch AR, White D, Kovacs MJ.

Leuk Lymphoma. 2008 Aug;49(8):1470-85. doi: 10.1080/10428190802064941. Review.

PMID:
18608859
20.

Treatment of relapsed/refractory multiple myeloma.

Kastritis E, Palumbo A, Dimopoulos MA.

Semin Hematol. 2009 Apr;46(2):143-57. doi: 10.1053/j.seminhematol.2009.01.004. Review.

PMID:
19389498

Supplemental Content

Support Center